Technical Analysis for DVAX - Dynavax Technologies Corporation

Grade Last Price % Change Price Change
D 8.88 -0.67% -0.06
DVAX closed down 0.67 percent on Thursday, May 6, 2021, on approximately normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Down
Historical DVAX trend table...

Date Alert Name Type % Chg
Earnings Movers Other 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Down 5 Days in a Row Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
MACD Bearish Centerline Cross Bearish -0.67%
Stochastic Reached Oversold Weakness -0.67%
Earnings Movers Other -0.67%
Down 3 Days in a Row Weakness -0.67%
Older End-of-Day Signals for DVAX ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Trending on StockTwits about 11 hours ago
Trending on StockTwits about 14 hours ago
Possible Pocket Pivot about 15 hours ago
60 Minute Opening Range Breakout about 19 hours ago
Lower Bollinger Band Support about 19 hours ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Dynavax Technologies Corporation Description

Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious and inflammatory diseases. It develops product candidates based on the use of immunostimulatory sequences and immunoregulatory sequences. Its lead product candidate is HEPLISAV, a Phase III investigational adult hepatitis B vaccine. The company also develops DV1179, a Phase I bifunctional inhibitor of TLR7 and TLR9 for the treatment of autoimmune and inflammatory diseases; and AZD1419, a preclinical drug candidate for the treatment of asthma. It has a strategic alliance with GlaxoSmithKline to discover, develop, and commercialize TLR inhibitors; and a research collaboration and license agreement with AstraZeneca AB for the discovery and development of TLR9 agonist-based therapies for the treatment of asthma and chronic obstructive pulmonary disease. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was founded in 1996 and is based in Berkeley, California.


Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Pharmaceutical Industry Inflammatory Disease Inflammatory Diseases Hepatitis B Asthma Pulmonary Disease Chronic Obstructive Pulmonary Disease Glaxosmithkline Autoimmune And Inflammatory Diseases Autoimmune And Inflammatory Disease Novel Products Tlr7 Tlr9

Is DVAX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 12.44
52 Week Low 3.55
Average Volume 2,938,564
200-Day Moving Average 6.83
50-Day Moving Average 9.67
20-Day Moving Average 9.90
10-Day Moving Average 9.72
Average True Range 0.64
ADX 15.86
+DI 20.05
-DI 32.11
Chandelier Exit (Long, 3 ATRs ) 9.93
Chandelier Exit (Short, 3 ATRs ) 10.40
Upper Bollinger Band 11.13
Lower Bollinger Band 8.67
Percent B (%b) 0.09
BandWidth 24.89
MACD Line -0.13
MACD Signal Line 0.02
MACD Histogram -0.1519
Fundamentals Value
Market Cap 978.34 Million
Num Shares 110 Million
EPS -2.56
Price-to-Earnings (P/E) Ratio -3.46
Price-to-Sales 10.74
Price-to-Book 6.76
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 9.60
Resistance 3 (R3) 9.55 9.26 9.48
Resistance 2 (R2) 9.26 9.08 9.29 9.44
Resistance 1 (R1) 9.07 8.97 9.17 9.12 9.40
Pivot Point 8.78 8.78 8.83 8.81 8.78
Support 1 (S1) 8.59 8.60 8.69 8.64 8.36
Support 2 (S2) 8.30 8.48 8.32 8.32
Support 3 (S3) 8.11 8.30 8.28
Support 4 (S4) 8.16